Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis

Paiva‐Santos, Ana Cláudia; Gama, Melissa; Peixoto, Diana; Sousa-Oliveira, Inês; Ferreira-Faria, Inês; Zeinali, Mahdi; Abbaspour‐Ravasjani, Soheil; Mascarenhas-Melo, Filipa; Hamishehkar, Hamed; Veiga, Francisco

doi:10.1016/j.ijpharm.2022.121656

Cited by 28 publications

(17 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By transporting drugs dispersed in oil droplets while passing through the gastrointestinal tract (GIT) [ 206 ], they enable prolonged drug release within the GIT—the drugs incorporated in the inner-oil phase must partition across multiple phases before reaching the site of action where drug release is desired [ 206 ]. For topical application, the formulation in principle does not require prolonged release since the formulation is directly applied to the affected area to establish a localised therapeutic effect [ 207 ]. Nevertheless, the capacity for prolonged drug release provided by SDEDDSs can establish the intended therapeutic effect by controlling drug release as well as enabling the release of multiple drugs [ 206 , 207 ].…”

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

“…For topical application, the formulation in principle does not require prolonged release since the formulation is directly applied to the affected area to establish a localised therapeutic effect [ 207 ]. Nevertheless, the capacity for prolonged drug release provided by SDEDDSs can establish the intended therapeutic effect by controlling drug release as well as enabling the release of multiple drugs [ 206 , 207 ]. Conrolled drug release into the skin will obviate erratic drug release which can result in unwanted systemic uptake of the applied drug [ 207 ].…”

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

“…Nevertheless, the capacity for prolonged drug release provided by SDEDDSs can establish the intended therapeutic effect by controlling drug release as well as enabling the release of multiple drugs [ 206 , 207 ]. Conrolled drug release into the skin will obviate erratic drug release which can result in unwanted systemic uptake of the applied drug [ 207 ]. Use of conventional topical formulations that do not have controlled release properties place focus on establishing direct skin penetration of the encapsulated drugs [ 207 ].…”

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

“…Conrolled drug release into the skin will obviate erratic drug release which can result in unwanted systemic uptake of the applied drug [ 207 ]. Use of conventional topical formulations that do not have controlled release properties place focus on establishing direct skin penetration of the encapsulated drugs [ 207 ]. In general, this is understandable as drugs must cross the protective barrier provided by the skin.…”

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

“…In general, this is understandable as drugs must cross the protective barrier provided by the skin. This barrier reduces entry of drugs into the deeper skin layers thereby limiting dermal bioavailability which also compromises therapeutic effectiveness [ 207 ]. Therefore, optimal selection of excipients accompanied by a refined pre-formulation approach for preparing the SDEDDSs should overcome the challenges posed by drug solubilization and skin lipid disruption, and enable sustained release required to achieve dermal drug delivery [ 204 , 205 , 207 ].…”

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

See 4 more Smart Citations

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems

2022

View full text Add to dashboard Cite

Although chemotherapeutic treatment regimens are currently available, and considerable effort has been lavished on the development of new drugs for the treatment of tuberculosis (TB), the disease remains deeply intractable and widespread. This is due not only to the nature of the life cycle and extraordinarily disseminated habitat of the causative pathogen, principally Mycobacterium tuberculosis (Mtb), in humans and the multi-drug resistance of Mtb to current drugs, but especially also to the difficulty of enabling universal treatment of individuals, immunocompromised or otherwise, in widely differing socio-economic environments. For the purpose of globally eliminating TB by 2035, the World Health Organization (WHO) introduced the “End-TB” initiative by employing interventions focusing on high impact, integrated and patient-centered approaches, such as individualized therapy. However, the extraordinary shortfall in stipulated aims, for example in actual treatment and in TB preventative treatments during the period 2018–2022, latterly and greatly exacerbated by the COVID-19 pandemic, means that even greater pressure is now placed on enhancing our scientific understanding of the disease, repurposing or repositioning old drugs and developing new drugs as well as evolving innovative treatment methods. In the specific context of multidrug resistant Mtb, it is furthermore noted that the incidence of extra-pulmonary TB (EPTB) has significantly increased. This review focusses on the potential of utilizing self-double-emulsifying drug delivery systems (SDEDDSs) as topical drug delivery systems for the dermal route of administration to aid in treatment of cutaneous TB (CTB) and other mycobacterial infections as a prelude to evaluating related systems for more effective treatment of CTB and other mycobacterial infections at large. As a starting point, we consider here the possibility of adapting the highly lipophilic riminophenazine clofazimine, with its potential for treatment of multi-drug resistant TB, for this purpose. Additionally, recently reported synergism achieved by adding clofazimine to first-line TB regimens signifies the need to consider clofazimine. Thus, the biological effects and pharmacology of clofazimine are reviewed. The potential of plant-based oils acting as emulsifiers, skin penetration enhancers as well as these materials behaving as anti-microbial components for transporting the incorporated drug are also discussed.

show abstract

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

Section: The Prospect Of Self-double-emulsifying Drug Delivery System...mentioning

confidence: 99%

See 3 more Smart Citations

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems

2022

View full text Add to dashboard Cite

show abstract

Biofunctional Inorganic Layered Double Hydroxide Nanohybrid Enhances Immunotherapeutic Effect on Atopic Dermatitis Treatment

Byun,

Seo,

Lee

et al. 2023

Small

View full text Add to dashboard Cite

Atopic dermatitis (AD) is a widespread, recurrent, and chronic inflammatory skin condition that imposes a major burden on patients. Conventional treatments, such as corticosteroids, are associated with various side effects, underscoring the need for innovative therapeutic approaches. In this study, the possibility of using indole‐3‐acetic acid‐loaded layered double hydroxides (IAA‐LDHs) is evaluated as a novel treatment for AD. IAA is an auxin‐class plant hormone with antioxidant and anti‐inflammatory effects. Following the synthesis of IAA‐LDH nanohybrids, their ability to induce M2‐like macrophage polarization in macrophages obtained from mouse bone marrow is assessed. The antioxidant activity of IAA‐LDH is quantified by assessing the decrease in intracellular reactive oxygen species levels. The anti‐inflammatory and anti‐atopic characteristics of IAA‐LDH are evaluated in a mouse model of AD by examining the cutaneous tissues, immunological organs, and cells. The findings suggest that IAA‐LDH has great therapeutic potential as a candidate for AD treatment based on its in vitro and in vivo modulation of AD immunology, enhancement of macrophage polarization, and antioxidant activity. This inorganic drug delivery technology represents a promising new avenue for the development of safe and effective AD treatments.

show abstract

Comprehensive review of the skin use of bakuchiol: physicochemical properties, sources, bioactivities, nanotechnology delivery systems, regulatory and toxicological concerns

Mascarenhas-Melo,

Ribeiro,

Kahkesh

et al. 2024

Phytochem Rev

View full text Add to dashboard Cite

Bakuchiol is a meroterpene that has recently aroused great interest in the cosmetic and pharmaceutical industries. Its main source is the seeds of Psoralea corylifolia, a medicinal plant native to Asia, despite having a wide geographical distribution. However, this medicinal herb faces endangerment due to low seed germination rates and high seedling mortality. In this context, this review article highlights studies that have focused on describing plant regeneration from root fragments. Subsequently, given its morphological similarity to other species, a technique that can be used to verify the authenticity of the plant and prevent counterfeiting is also mentioned and explored. Additionally, a “green” extraction method for obtaining bakuchiol is presented, and the possibility of obtaining bakuchiol through chemical synthesis routes is also explored. Furthermore, we provide an exhaustive description of bakuchiol's wide range of biological activities, with particular relevance to the skin. The main skin bioactivities of bakuchiol include antifungal, antibacterial, antioxidant, anti-inflammatory, antiaging, depigmenting, and anticancer. However, the particular physicochemical properties of bakuchiol require and benefit from the development of innovative skin delivery systems that allow its encapsulation. These include micro- and nano-sized systems for therapeutic and cosmetic applications, which are also carefully described in this review article. Finally, regulatory issues, metabolic considerations, and toxicological concerns related to the use of bakuchiol in cosmetic and dermopharmaceutical formulations will be addressed, relating not only to the user but also to the environment. Graphical abstract

show abstract

Nanocarrier-based dermopharmaceutical formulations for the topical management of atopic dermatitis

Cited by 28 publications

References 78 publications

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems

Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems

Biofunctional Inorganic Layered Double Hydroxide Nanohybrid Enhances Immunotherapeutic Effect on Atopic Dermatitis Treatment

Comprehensive review of the skin use of bakuchiol: physicochemical properties, sources, bioactivities, nanotechnology delivery systems, regulatory and toxicological concerns

Contact Info

Product

Resources

About